Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Boianelli

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|September 28, 2025
Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonistWeier Qi, Simina M Boca, Alessandro Boianelli, et al.
JCI Insight|October 17, 2024
Knockdown of ketohexokinase versus inhibition of its kinase activity exert divergent effects on fructose metabolismSe-Hyung Park, Taghreed Fadhul, Lindsey R Conroy, et al.
Diabetes, Obesity & Metabolism|November 4, 2024
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonistAmina Z Haggag, Jianfeng Xu, Laurie Butcher, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|September 28, 2025
Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonistWeier Qi, Simina M Boca, Alessandro Boianelli, et al.
JCI Insight|October 17, 2024
Knockdown of ketohexokinase versus inhibition of its kinase activity exert divergent effects on fructose metabolismSe-Hyung Park, Taghreed Fadhul, Lindsey R Conroy, et al.
Diabetes, Obesity & Metabolism|November 4, 2024
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonistAmina Z Haggag, Jianfeng Xu, Laurie Butcher, et al.
Pageof 2